Gossamer Bio Inc
$ 3.23
-6.10%
26 Dec - close price
- Market Cap 747,604,000 USD
- Current Price $ 3.23
- High / Low $ 3.46 / 3.14
- Stock P/E N/A
- Book Value -0.36
- EPS -0.69
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -7.83 %
- 52 Week High 3.87
- 52 Week Low 0.76
About
Gossamer Bio, Inc. is a San Diego-based clinical-stage biopharmaceutical company dedicated to advancing innovative therapies targeting immunology, inflammation, and oncology. With a promising pipeline driven by cutting-edge scientific discovery, Gossamer Bio aims to address significant unmet medical needs through its diverse array of drug candidates. As the company navigates clinical trials, it is positioned to offer transformative treatment options for patients dealing with complex diseases, reinforcing its role as a key player in the competitive biopharmaceutical landscape.
Analyst Target Price
$9.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-05 | 2025-05-05 | 2025-03-03 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-03-05 | 2023-11-09 | 2023-08-08 | 2023-05-09 | 2023-03-17 |
| Reported EPS | -0.21 | -0.17 | -0.16 | -0.15 | -0.14 | 0.22 | -0.19 | -0.21 | -0.21 | -0.45 | -0.52 | -0.59 |
| Estimated EPS | -0.1887 | -0.1805 | -0.19 | -0.168 | -0.15 | 0.23 | -0.19 | -0.21 | -0.26 | -0.49 | -0.53 | -0.62 |
| Surprise | -0.0213 | 0.0105 | 0.03 | 0.018 | 0.01 | -0.01 | 0 | 0 | 0.05 | 0.04 | 0.01 | 0.03 |
| Surprise Percentage | -11.2878% | 5.8172% | 15.7895% | 10.7143% | 6.6667% | -4.3478% | 0% | 0% | 19.2308% | 8.1633% | 1.8868% | 4.8387% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GOSS
2025-12-24 00:09:34
Gossamer Bio Inc. (NASDAQ: GOSS) stock is experiencing a downturn despite strategic realignments and increased investor optimism in the biotech sector. The company faces significant financial challenges, reporting a net loss of $48.2M in Q3 2025 and negative profit margins, yet analysts point to R&D prioritization and strategic alliances as potential paths to recovery. The article emphasizes the importance of disciplined trading and continuous learning amidst market fluctuations.
2025-12-22 03:09:34
Corient Private Wealth LLC significantly increased its stake in Gossamer Bio, Inc. (NASDAQ:GOSS) by 8.9%, bringing its total holdings to 3,693,683 shares valued at $4.543 million. This purchase, alongside substantial buys from other institutions like Goldman Sachs, highlights increasing institutional interest in the biopharmaceutical company, which has a "Moderate Buy" consensus rating and an average target price of $8.50 from analysts despite reporting negative earnings.
2025-12-22 01:09:10
Gossamer Bio, Inc. (NasdaqGS: GOSS) has been added to the S&P Biotechnology Select Industry Index. The company is a clinical-stage biopharmaceutical firm focusing on the development and commercialization of seralutinib for pulmonary arterial hypertension (PAH). This inclusion indicates growing recognition and potential visibility for Gossamer Bio within the biotechnology sector.
2025-12-21 07:31:00
Gossamer Bio, Inc. (NASDAQ: GOSS) is garnering strong analyst confidence as it progresses with its seralutinib programs for pulmonary hypertension, including completing enrollment for its Phase 3 PROSERA study and activating its Phase 3 SERANATA study. Analysts from Piper Sandler and H.C. Wainwright have reiterated "Buy" ratings, citing upcoming data readouts and broadening clinical scope as key milestones. The company expects topline PROSERA data in February 2026.
2025-12-19 09:10:25
Gossamer Bio, Inc. (NASDAQ:GOSS) has received a "Moderate Buy" consensus rating from six analytical firms, with an average 12-month price target of $8.50. The company shows significant institutional ownership and recent buying activity from major hedge funds. Despite negative earnings, Gossamer Bio exceeded revenue estimates in its latest quarterly report.
2025-12-16 05:09:19
Oppenheimer maintains confidence in a positive readout for Gossamer Bio's PROSERA trial in February 2026, citing strong baseline characteristics and positive Phase 2 TORREY data, which support the likelihood of achieving the primary endpoint. The company has also started its Phase 3 SERANATA/PH-ILD trial and reported Q3 2025 revenue of $13.3 million, surpassing estimates, despite a wider net loss.
